

---

## Changing trends in clinico-morphological profile of chronic myeloid leukemia-our experience

DOI: 10.4103/2278-330X.173176

Dear Editor,

The true incidence of chronic myeloid leukemia (CML) in India is not available. According to 6 population-based cancer registries, the incidence of CML in India varies from 0.8 to 2.2/1,00,000 population for men and from 0.6 to 1.6/1,00,000 population for women.<sup>[1]</sup> Hospital-based studies have reported a higher frequency of CML ranging from 40% to 82% of all cases of leukemia among adults.<sup>[2]</sup>

A total of 68 patients diagnosed with CML were studied. Out

of these, 36 were females and 32 males. The age range at presentation was 11–70 years of median age of 35 years at diagnosis. The maximum number of patients presented in the third decade (n-15) followed by fourth decade. Out of 68 patients, 39 (57%) presented in chronic phase (CP) at the time of diagnosis, 10 in accelerated and 19 in blast crisis (BC) [Table 1]. Fever was the most common symptom present in 27% of patients followed by abdominal fullness and pain (18%), bleeding manifestations (11%), bony pains (9%) and thrombotic events (6%). 9% patients were asymptomatic. On examination, moderate to massive splenomegaly was present in 34 (50%) patients whereas 6 (9%) patients in CP did not have a palpable spleen. Massive splenomegaly was found in 62% of patients in accelerated and BC as compared to 38% patients in CP.

South Asian Journal of Cancer ♦ July-September 2015 ♦ Volume 4 ♦ Issue 3

**Table 1: Frequency of three phases of CML with age and gender distribution**

Age	Male	Female	CP	AP	BC
0-10	-	-	-	-	-
11-20	9	4	7	3	3
21-30	5	10	8	4	3
31-40	5	9	7	2	5
41-50	10	3	7	-	6
>50	3	10	10	1	2
Total	32	36	39	10	19

CML=Chronic myeloid leukemia, CP=Chronic phase, AP=Accelerated phase, BC=Blast crisis

**Table 2: Peripheral blood findings in patients according to phases**

Value	CP (n=39)	AP (n=10)	BC (n=19)
Hb (g/dl) range	5.5-13.0	6.1-12.0	5.6-11.3
Mean±SD	9.4±4.8	8.6±4.1	8.9±2.6
Number of patients with Hb			
<10 g/dl	27	09	17
>10 g/dl	12	01	02
Platelets ( $\times 10^5/\mu\text{l}$ ) range	0.6-6.2	1.0-5.0	0.1-4.4
Mean±SD	3.21±1.9	2.76±1.8	2.14±2.2
Number of patients with platelets			
<1.5	03	01	05
>1.5	36	09	14

Hb=Hemoglobin, SD=Standard deviation, CP=Chronic phase, AP=Accelerated phase, C=Blast crisis

Also, patients in the younger age group had bigger spleens as compared to old (65% vs. 42%). 11 patients also had significant lymphadenopathy, most commonly involving the inguinal group. Hemoglobin (Hb) level was in the range of 5.5–13.0 g/dl ( $9.4 \pm 4.8$ ). Mean Hb levels did not differ much among the three phases [Table 2]. Average platelet count in younger group was significantly higher than in the older age group (mean  $3.63 \times 10^5/\mu\text{l} \pm 1.99$  vs.  $2.62 \times 10^5/\mu\text{l} \pm 1.40$ ;  $P = 0.01$ ) [Table 2].

Available data suggest that the epidemiology of CML is different in the Indian subcontinent and in other developing countries from that of the rest of the world.<sup>[3]</sup> In our study, the median age was 35 years (range 11–70 years) which is significantly lower than reported in European<sup>[4]</sup> (median age 55 years) and American literature<sup>[5]</sup> (median age 66 years). In the study by Bhutani *et al.*, the median age of onset is 38 years in India<sup>[2]</sup> while in a regional study in Pakistan mean age was 37.87 years which is quite less than the age of presentation in west.<sup>[6]</sup> Shorter life expectancy,

under diagnosis in older people or a high prevalence of chronic infection in this population may be some of the reasons for younger age at presentation.<sup>[7]</sup> The frequency of all three phases of CML that is, CP, accelerated phase and BC in our study was 57%, 15% and 28% respectively as compared to 96.8%, 2.2% and 0.9% respectively in a French study.<sup>[3]</sup> The western literature describes bleeding manifestations to be more common in comparison to thrombotic events.<sup>[7]</sup> There are significant differences in age and phases at presentation in comparison to west.

#### Financial support and sponsorship

Nil.

#### Conflicts of interest

There are no conflicts of interest.

**Anshu Palta, Pratibha Dhiman, Phiza Aggarwal, Monica Gupta**

Department of Pathology and Medicine, Government Medical College and Hospital-32, Chandigarh, India

Correspondence to: Dr. Pratibha Dhiman,  
E-mail: dhimandrpratibha@yahoo.com

#### References

1. Two Years Report of Population Based Cancer Registries, 1999-2000. New Delhi: Indian Council of Medical Research, National Cancer Registry Programme; 2005.
2. Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. *Med Oncol* 2002;19:141-50.
3. Aziz Z, Iqbal J, Akram M, Saeed S. Treatment of chronic myeloid leukemia in the imatinib era: Perspective from a developing country. *Cancer* 2007;109:1138-45.
4. Tardieu S, Brun-Strang C, Berthaud P, Michallet M, Guilhot F, Rousselot P, *et al.* Management of chronic myeloid leukemia in France: A multicentered cross-sectional study on 538 patients. *Pharmacoepidemiol Drug Saf* 2005;14:545-53.
5. Cortes JE, Richard TS, Hagop K. Chronic myelogenous leukemia. In: Padzur R, Coia LR, Hoskins WJ, Wagman LD, editors. *Cancer Management: a Multidisciplinary Approach*. 10<sup>th</sup> ed. Lawrence: CMP Medica; 2007. p. 789.
6. Ahmed R, Naqi N, Hussain I, Khattak BK, Nadeem M, Iqbal J. Presenting phases of chronic myeloid leukaemia. *J Coll Physicians Surg Pak* 2009;19:469-72.
7. Malhotra P, Varma S. Chronic myeloid leukaemia in India. *Lancet* 2007;370:1127.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**How to cite this article:** Palta A, Dhiman P, Aggarwal P, Gupta M. Changing trends in clinico-morphological profile of chronic myeloid leukemia-our experience. *South Asian J Cancer* 2015;4:150-1.